Atıf İçin Kopyala
KOCA S. S., Özgen M., Dagli A. F., GÖZEL N., ÖZERCAN İ. H., Isik A.
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, cilt.25, sa.2, ss.249-253, 2016 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
25
Sayı:
2
-
Basım Tarihi:
2016
-
Doi Numarası:
10.17219/acem/32484
-
Dergi Adı:
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.249-253
-
Anahtar Kelimeler:
bevacizumab, scleroderma, dermal fibrosis, VEGF, MICROVASCULAR ENDOTHELIAL-CELLS, SYSTEMIC-SCLEROSIS, GROWTH-FACTOR, ANGIOGENESIS, DIFFERENTIATION, PATHOGENESIS, DISEASE, ULCERS
-
Ondokuz Mayıs Üniversitesi Adresli:
Evet
Özet
Background. The capillary networks are less dense and have irregular structures in scleroderma. These abnormalities result in lower capillary blood flow causing severe tissue hypoxia, which is a major stimulus for angiogenesis. However, current knowledge about compensatory angiogenesis is ambiguous in scleroderma. Bevacizumab is an inhibitor of vascular endothelial growth factor (VEGF).